DUPLEX-ADJNJ-95475939 pour la dermatite atopique modérée à sévère

Dupilumab

JNJ-95475939

JNJ-95475939

JNJ-95475939

JNJ-95475939

Placebo

Percentage of Participants with Eczema Area and Severity Index (EASI) 75 Response at Week 12

Percentage of Participants With EASI-90 Response at Week 12

Percentage of Participants With EASI-100 Response at Week 12

Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 or 1 and a Reduction From Baseline of Greater Than Equal to (>=) 2 Points at Week 12

Percentage of Participants Achieving a >= 4-Point Reduction in Skin Pain Numerical Rating Scale (NRS) Score From Baseline to Week 16

Percentage of Participants Achieving vIGA-AD Score of 0 and a Reduction From Baseline of >= 2 Points at Week 12

Percent Change From Baseline in the EASI Total Score at Week 12

Percentage of Participants Achieving a >= 4-Point Reduction in Skin Pain Numerical Rating Scale (NRS) Score From Baseline to Week 12

Percent Change from Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 12

Percent Change from Baseline in Skin Pain NRS Score at Week 12

Percent Change from Baseline in the Score of Item 2 of the AD Sleep Scale at Week 12

Percentage of Participants Achieving a >= 4-Point Reduction in PP-NRS Score From Baseline Through Week 12

Percentage of Participants with EASI-75 Response at Week 16

Percentage of Participants with EASI-90 Response at Week 16

Percentage of Participants with EASI-100 Response at Week 16

Percentage of Participants Achieving vIGA-AD Score of 0 or 1 and a Reduction From Baseline of >= 2 Points at Week 16

Percentage of Participants Achieving vIGA-AD Score of 0 and a Reduction From Baseline of >= 2 Points at Week 16

Percent Change from Baseline in the EASI Total Score at Week 16

Percent Change from Baseline in PP-NRS Score at Week 16

Percent Change from Baseline in Skin Pain NRS Score at Week 16

Percent Change from Baseline in the Score of Item 2 of the AD Sleep Scale at Week 16

Percentage of Participants Achieving a >= 4-Point Reduction in PP-NRS Score From Baseline Through Week 24

Percentage of Participants with EASI-75 Response at Week 24

Percentage of Participants with EASI-90 Response at Week 24

Percentage of Participants with EASI-100 Response at Week 24

Percentage of Participants Achieving vIGA-AD Score of 0 or 1 and a Reduction From Baseline of >= 2 Points at Week 24

Percentage of Participants Achieving vIGA-AD Score of 0 and a Reduction From Baseline of >= 2 Points at Week 24

Percent Change from Baseline in the EASI Total Score at Week 24

Percentage of Participants Achieving a >= 4-Point Reduction in Skin Pain NRS Score From Baseline to Week 24

Percent Change From Baseline in PP-NRS Score at Week 24

Percent Change from Baseline in Skin Pain NRS Score at Week 24

Percent Change from Baseline in the Score of Item 2 of the AD Sleep Scale at Week 24

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)